Data Sheet (Cat.No.T2312)

TargetMol

Loxiglumide

Chemical Properties



CAS No. : 107097-80-3

Formula: C21H30Cl2N2O5

Molecular Weight: 461.38

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Loxiglumide (CR-1505) is an antagonist of cholecystokinin (CCK-1) receptor.
Targets(IC50)	Cholecystokinin Receptor
Kinase Assay	Kinase binding assays: For optimization of Axl/TAM receptor inhibitors, an Axl binding assay is established (HTRF method; Kinase tracer 236). This assay is based on the binding and displacement of the Alexa Fluor 647-labelled Kinase tracer 236 to each glutathione S-transferase (GST)-tagged kinase used in the binding assay. Binding of the tracer to the kinase was detected by using europium (Eu)-labelled anti-GST antibodies. Simultaneous binding of both the fluorescent tracer and the Eu-labelled antibodies to the GST-tagged kinase generates a fluorescence resonance energy transfer (FRET) signal. Binding of inhibitor to the kinase competes for binding with the tracer, resulting in a loss of the FRET signal. For the assay, the compound is diluted in 20?mM HEPES, pH? 8.0, 1?mM DTT, 10?mM MgCl2 and 0.01% Brij35. Then, the kinase of interest (5?nM final concentration), fluorescent tracer (15?nM final concentration) and LanthaScreen Eu-anti-GST antibody (2?nM final concentration) are mixed with the respective compound dilutions (from 5?nM to 10?μM) and incubated for 1?h. The FRET signal is quantified using an EnVision Multilabellreader 2104.

Solubility Information

Solubility	DMSO: 4.62 mg/mL (10.01 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.17 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1674 mL	10.8371 mL	21.6741 mL
5 mM	0.4335 mL	2.1674 mL	4.3348 mL
10 mM	0.2167 mL	1.0837 mL	2.1674 mL
50 mM	0.0433 mL	0.2167 mL	0.4335 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Teyssen S, et al. Pancreas. 1996 Nov;13(4):407-16.2. Shiratori K, et al. Pancreas. 2002 Jul;25(1):e1-5.